ABL Bio Inc. (ABL Bio) Aktie

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.